A decades-old TB vaccine turned cancer therapy may unlock new immunotherapies by reprogramming immune cell development in the ...

Details of the oral presentation are as follows ... monotherapy for patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Abstract Number ...

Oral presentation from QUILT-3.032 study showed 71% complete response rate (N=100), with duration of response ranging up to more than 53 months, in BCG-unresponsive NMIBC CIS with or without ...

and generated draft presentations in minutes, reducing a two-week process to two or three days. Another striking example of AI's impact at BCG is the development of Gene, a conversational AI ...

Bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer with carcinoma in situ, according to a news release from CG Oncology, Inc. In a presentation of data given at the 40th ...

with BCG alone (induction and maintenance). Results from the CREST trial are being presented today in a plenary oral presentation at the 2025 American Urological Association (AUA) Annual Meeting.

A massive opportunity lies ahead for the Indian workforce as high-income countries are projected to face a labour shortage of ...

and Intel worked together on similar technology so that BCG's employees could put the group's half century worth of archives - much of which is in the form of reports and presentations - to better ...